KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBITDA (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EBITDA for 7 consecutive years, with $210.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 17975.75% year-over-year to $210.9 million, compared with a TTM value of $287.2 million through Dec 2025, up 4822.88%, and an annual FY2025 reading of $287.2 million, up 4822.88% over the prior year.
  • EBITDA was $210.9 million for Q4 2025 at Aurinia Pharmaceuticals, up from $31.7 million in the prior quarter.
  • Across five years, EBITDA topped out at $210.9 million in Q4 2025 and bottomed at -$86.4 million in Q4 2021.
  • Average EBITDA over 5 years is -$6.4 million, with a median of -$12.4 million recorded in 2023.
  • The sharpest move saw EBITDA plummeted 94.25% in 2021, then skyrocketed 17975.75% in 2025.
  • Year by year, EBITDA stood at -$86.4 million in 2021, then skyrocketed by 70.4% to -$25.6 million in 2022, then decreased by 4.21% to -$26.7 million in 2023, then skyrocketed by 104.38% to $1.2 million in 2024, then surged by 17975.75% to $210.9 million in 2025.
  • Business Quant data shows EBITDA for AUPH at $210.9 million in Q4 2025, $31.7 million in Q3 2025, and $21.4 million in Q2 2025.